Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Business Wire
– The review provides strong scientific rationale to support Alto’s drug development approach leveraging its Precision Psychiatry Platform – MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience’s leadership team, Patricio O’Donnell, M.D., Ph.D, and Amit Etkin, M.D., Ph.D., as well as Husseini Manji, M.D., former global head of therapeutics, neuroscience at Janssen and a member of Alto’s board of directors.The article consolidates extensive clinical and translational evidence demonstrating that disrupted neuroplasticity—spanning synaptic, cellular, and circuit-level dysfunction—
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment [Yahoo! Finance]Yahoo! Finance
- Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)GlobeNewswire
- Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression [Yahoo! Finance]Yahoo! Finance
- Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in DepressionBusiness Wire
- Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology [Yahoo! Finance]Yahoo! Finance
ANRO
Earnings
- 11/12/25 - Beat
ANRO
Sec Filings
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- 1/6/26 - Form 4
- ANRO's page on the SEC website